AstraZeneca accelerating ambition in oncology cell therapy with M&A deal

Marking its third M&A deal so far this year, UK pharma major AstraZeneca (LSE: AZN) today revealed it is to acquire Neogene Therapeutics, a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting cancer.

With a shared goal of bringing cell therapies to patients with solid tumors, Neogene’s expertise in TCR-T discovery, development and manufacturing will strengthen AstraZeneca’s ambition to transform outcomes for patients.

AstraZeneca’s shares edged up 0.7% to 11,132.00 pence on the news. Earlier this year, the company announced it was acquiring LogicBio and TeneoTwo.